• Skip to primary navigation
  • Skip to main content

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • SAGES Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
      • SAGES Robotics Residents and Fellows Courses
      • MIS Fellows Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • Search
    • Search the SAGES Site
    • Guidelines Search
    • Video Search
    • Search Images
    • Search Abstracts
  • OWLS/FLS
  • Login
You are here: Home / Abstracts / The Effect of Inhaled Lps on the Development of Bronchiolitis Obliterans.

The Effect of Inhaled Lps on the Development of Bronchiolitis Obliterans.

Introduction: Gastroesophageal reflux-associated chronic aspiration contributes to the development of various lung disease processes including chronic pulmonary allograft dysfunction, as manifested by the histologic finding of bronchiolitis obliterans (BO). The TLR-4 innate immune pathway is thought to play a role in these processes and may be activated by bacteria within the gastric contents. Here we examine whether LPS, a TLR-4 agonist found in bacteria, leads to the progression of BO when inhaled by rats with left lung allografts.
Methods: Thirteen F344 rats underwent left lung transplantation using WKY rat donors. Three times a week for 15 weeks, starting 1 week after the transplant, rats were exposed for 1 hour to an aerosolized solution of either LPS or sterile 0.9% saline. All rats were given 5mg/kg cyclosporine three times weekly. After 15 weeks, all rats were sacrificed, and tissue from each lobe of transplanted and native lungs was prepared for pathologic review. A board-certified pathologist then graded every visible airway on all slides on a scale from 0 (no BO) to 3 (severe BO) in a blinded fashion.
Results: Comparison of LPS- and saline-treated animals revealed no difference in overall BO disease burden, defined as number of diseased (grade 1-3) airways divided by the total number of airways, in allograft lungs (p=0.949, by unpaired t-test). However, there was a trend toward greater BO disease burden in native (non-transplanted) lungs in LPS-treated animals than in saline-treated animals (p=0.119 by unpaired t-test). LPS also caused a trend towards inducing severe (grade 3) BO lesions (p=0.053 by X2 contingency table), all of which were found in the native rather than the transplanted lungs (p=0.014 by X2 contingency table).
Conclusions: These data demonstrate that inhaled LPS alone, as a component that triggers the innate immune pathway, is not sufficient to induce BO in pulmonary allografts under the conditions used. The findings do suggest that exposure to LPS may play a role in generating a response in non-transplanted lungs in single lung allograft recipients. These observations merit further study and suggest that innate immune pathways in the native lung contribute to pulmonary pathology.


Session: Poster

Program Number: P107

View Poster

163


  • Foundation
  • SAGES.TV
  • MyCME
  • Educational Activities

Copyright © 2025 Society of American Gastrointestinal and Endoscopic Surgeons